Does OSIMERTINIB Cause Interstitial lung disease? 573 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 573 reports of Interstitial lung disease have been filed in association with OSIMERTINIB (TAGRISSO). This represents 2.1% of all adverse event reports for OSIMERTINIB.
573
Reports of Interstitial lung disease with OSIMERTINIB
2.1%
of all OSIMERTINIB reports
221
Deaths
305
Hospitalizations
How Dangerous Is Interstitial lung disease From OSIMERTINIB?
Of the 573 reports, 221 (38.6%) resulted in death, 305 (53.2%) required hospitalization, and 77 (13.4%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
Yes, Interstitial lung disease is listed as a known adverse reaction in the official FDA drug label for OSIMERTINIB.
What Other Side Effects Does OSIMERTINIB Cause?
Death (10,423)
Malignant neoplasm progression (2,920)
Diarrhoea (1,408)
Drug resistance (1,026)
Fatigue (819)
Rash (772)
Decreased appetite (706)
Drug ineffective (627)
Dyspnoea (621)
Nausea (610)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which OSIMERTINIB Alternatives Have Lower Interstitial lung disease Risk?
OSIMERTINIB vs OSPEMIFENE
OSIMERTINIB vs OSPHENA
OSIMERTINIB vs OVINE DIGOXIN IMMUNE FAB
OSIMERTINIB vs OXACILLIN
OSIMERTINIB vs OXALIPLATIN